Rutin

Rutin

SCHEMBL796642

CC1O[C@@H](OCC2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)C(O)[C@H](O)[C@@H]2O)C(O)[C@@H](O)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 1.00
XDH P47989 4/20 1.00
MAOA P21397 3/20 1.00
EPHX2 P34913 3/20 1.00
MAPT P10636 2/20 1.00
HES1 Q14469 2/20 1.00
FANCF Q9NPI8 2/20 1.00
POLB P06746 2/20 1.00
GAA P10253 2/20 1.00
KDM1A O60341 1/20 1.00
PRSS1 P07477 1/20 1.00
PRSS2 P07478 1/20 1.00
ADRA2A P08913 1/20 1.00
HMGB1 P09429 1/20 1.00
CFTR P13569 1/20 1.00
ADRA2C P18825 1/20 1.00
ACHE P22303 1/20 1.00
MAPK1 P28482 1/20 1.00
PRSS3 P35030 1/20 1.00
BACE1 P56817 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rutin SCHEMBL15263233 1.00 KDM4E (1.00) KDM4EXDHMAOAEPHX2MAPT
Rutin SCHEMBL13696608 1.00 KDM4E (1.00) KDM4EXDHMAOAEPHX2MAPT
Rutin SCHEMBL802819 1.00 KDM4E (1.00) KDM4EXDHMAOAEPHX2MAPT
Rutin SCHEMBL20576343 1.00 KDM4E (1.00) KDM4EXDHMAOAEPHX2MAPT
Rutin SCHEMBL13696392 1.00 KDM4E (1.00) KDM4EXDHMAOAEPHX2MAPT
Rutin SCHEMBL21424757 1.00 KDM4E (1.00) KDM4EXDHMAOAEPHX2MAPT
Rutin SCHEMBL23663918 1.00 KDM4E (1.00) KDM4EXDHMAOAEPHX2MAPT
Rutin SCHEMBL21013017 1.00 KDM4E (1.00) KDM4EXDHMAOAEPHX2MAPT
Rutin SCHEMBL21325433 1.00 KDM4E (1.00) KDM4EXDHMAOAEPHX2MAPT
Rutin SCHEMBL21699244 1.00 KDM4E (1.00) KDM4EXDHMAOAEPHX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11819511-B2 Composition of N-palmitoyl-ethanolamide and Rutin in co-micronized form EPITECH GROUP S.P.A. (IT) 2023-11-21 US disclosed
US-20180064774-A1 COMPOSITIONS FOR USE IN THE TREATMENT OF TUMORS RESISTANT TO CHEMOTHERAPY PROBIOTICAL S.P.A. (IT) 2018-03-08 US disclosed
US-9828407-B2 Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives LIBRAGEN (FR) 2017-11-28 US disclosed
US-9757405-B2 Compositions comprising rutin useful for the treatment of tumors resistant to chemotherapy PROBIOTICAL S.P.A. (IT) 2017-09-12 US disclosed
US-20170209416-A1 COMPOSITIONS COMPRISING MELATONIN AND FLAVONOIDS FOR USE IN THE TREATMENT OF TUMOURS RESISTANT TO CHEMOTHERAPY PROBIOTICAL S.P.A. (IT) 2017-07-27 US disclosed
US-9707316-B2 Crosslinked polymers including one or more antioxidants, methods for making same and methods for selecting antioxidants ZIMMER, INC. (US) 2017-07-18 US disclosed
US-20160250381-A1 CROSSLINKED POLYMERS INCLUDING ONE OR MORE ANTIOXIDANTS, METHODS FOR MAKING SAME AND METHODS FOR SELECTING ANTIOXIDANTS ZIMMER INC (US) 2016-09-01 US disclosed
US-20160213698-A1 COMPOSITIONS COMPRISING RUTIN USEFUL FOR THE TREATMENT OF TUMORS RESISTANT TO CHEMOTHERAPY PROBIOTICAL S.P.A. (IT) 2016-07-28 US disclosed
US-9370602-B2 Crosslinked polymers including one or more antioxidants, methods for making same and methods for selecting antioxidants ZIMMER, INC. (US) 2016-06-21 US disclosed
US-9040489-B2 Nanocrystalline photocatalytic colloid, a method of producing it and its use JAGIELLONIAN UNIVERSITY (PL) 2015-05-26 US disclosed
US-9012120-B2 Production process of toner for electrostatic image development KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2015-04-21 US disclosed
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES LIBRAGEN (FR) 2014-03-27 US disclosed
US-20130122073-A1 COMPOSITION IN THE FORM OF LIQUID FOR MAINTENANANCE OF CONTACT LENSES AND MEDICAL MATERIALS UNIWERSYTET JAGIELLONSKI (PL) 2013-05-16 US disclosed
US-20120071428-A1 NANOCRYSTALLINE PHOTOCATALYTIC COLLOID, A METHOD OF PRODUCING IT AND ITS USE JAGIELLONIAN UNIVERSITY (PL) 2012-03-22 US disclosed
US-20110183930-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES LIBRAGEN (FR) 2011-07-28 US disclosed
US-20080139664-A1 ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064774-A1 COMPOSITIONS FOR USE IN THE TREATMENT OF TUMORS RESISTANT TO CHEMOTHERAPY SLC11A2, HES1, MTDH KDM4E 3205/4885XDH 335/4885MAOA 2786/4885
US-20080139664-A1 ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS AGER, GID4, GALE KDM4E 1615/4885XDH 1066/4885MAOA 197/4885
US-11819511-B2 Composition of N-palmitoyl-ethanolamide and Rutin in co-micronized form EPN1, CNR2, NAPEPLD KDM4E 4459/4885XDH 4555/4885MAOA 586/4885
US-20120071428-A1 NANOCRYSTALLINE PHOTOCATALYTIC COLLOID, A METHOD OF PRODUCING IT AND ITS USE UROD, CRYZ, CRYAB KDM4E 1774/4885XDH 4649/4885MAOA 1830/4885
US-20110183930-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES UGGT1, TYR, G6PD KDM4E 949/4885XDH 166/4885MAOA 688/4885
US-20130122073-A1 COMPOSITION IN THE FORM OF LIQUID FOR MAINTENANANCE OF CONTACT LENSES AND MEDICAL MATERIALS MLEC, CRYZ, LAGE3 KDM4E 2366/4885XDH 554/4885MAOA 1996/4885
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES UGGT1, TYR, G6PD KDM4E 949/4885XDH 166/4885MAOA 688/4885
US-20160213698-A1 COMPOSITIONS COMPRISING RUTIN USEFUL FOR THE TREATMENT OF TUMORS RESISTANT TO CHEMOTHERAPY SLC11A2, ABCC1, VHL KDM4E 4553/4885XDH 2493/4885MAOA 4250/4885
US-20170209416-A1 COMPOSITIONS COMPRISING MELATONIN AND FLAVONOIDS FOR USE IN THE TREATMENT OF TUMOURS RESISTANT TO CHEMOTHERAPY MTNR1B, MTNR1A, EGLN2 KDM4E 2691/4885XDH 655/4885MAOA 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.